Regeneron Pharmaceuticals (MIL:1REGN) Other Long Term Assets : €4,473 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Regeneron Pharmaceuticals Other Long Term Assets?

Regeneron Pharmaceuticals's other long-term assets for the quarter that ended in Mar. 2025 was €4,473 Mil.

Regeneron Pharmaceuticals's quarterly other long-term assets increased from Sep. 2024 (€3,656 Mil) to Dec. 2024 (€4,250 Mil) and increased from Dec. 2024 (€4,250 Mil) to Mar. 2025 (€4,473 Mil).

Regeneron Pharmaceuticals's annual other long-term assets increased from Dec. 2022 (€1,945 Mil) to Dec. 2023 (€2,769 Mil) and increased from Dec. 2023 (€2,769 Mil) to Dec. 2024 (€4,250 Mil).

Regeneron Pharmaceuticals Other Long Term Assets Historical Data

The historical data trend for Regeneron Pharmaceuticals's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Other Long Term Assets Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long Term Assets

Get a 7-Day Free Trial

844.20

967.30

1,944.74

2,768.88

4,249.84

Regeneron Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long Term Assets	Get a 7-Day Free Trial															2,976.29	3,599.60	3,656.35	4,249.84	4,473.30

Regeneron Pharmaceuticals Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MIL:1REGN) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico 0R2M:UK RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines